The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
p53 Status and the Efficacy of Cancer Therapy in Vivo
Abstract
The therapeutic responsiveness of genetically defined tumors expressing or devoid of the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors expressing the p53 gene contained a high proportion of apoptotic cells and typically regressed after treatment with gamma radiation or adriamycin. In contrast, p53-deficient tumors treated with the same regimens continued to enlarge and contained few apoptotic cells. Acquired mutations in p53 were associated with both treatment resistance and relapse in p53-expressing tumors. These results establish that defects in apoptosis, here caused by the inactivation of p53, can produce treatment-resistant tumors and suggest that p53 status may be an important determinant of tumor response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationApoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755
Self-citationMice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis
Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C.-C., Herrup, K., Lee, W.-H., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,265
Requirement for a functional Rb-1 gene in murine development
Clarke, A. R., Maandag, E. R., van Roon, M., van der Lugt, N. M. T., van der Valk, M., Hooper, M. L., Berns, A., & te Rielef, H. (1992) · Nature · doi:10.1038/359328a0 · Cited by 1,008
p53-Dependent apoptosis suppresses tumor growth and progression in vivo
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., & Van Dyke, T. (1994) · Cell · doi:10.1016/0092-8674(94)90534-7 · Cited by 880
Self-citationp53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 839
Cited by
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Self-citationDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Self-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
The role of apoptosis in cancer development and treatment response
Brown, J. M., & Attardi, L. D. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1560 · Cited by 944
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Proteins of the Myc Network: Essential Regulators of Cell Growth and Differentiation
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60353-x · Cited by 779
Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Lim, D.-S., & Hasty, P. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.7133 · Cited by 696
The genetics of the p53 pathway, apoptosis and cancer therapy
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 676
Oxidative Stress in Cancer Cell Metabolism
Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021) · Antioxidants · doi:10.3390/antiox10050642 · Cited by 665
Twenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
Central role of p53 in the suntan response and pathologic hyperpigmentation
Cui, R., Widlund, H. R., Feige, E., Lin, J. Y., Wilensky, D. L., Igras, V. E., D'Orazio, J., Fung, C. Y., Schanbacher, C. F., Granter, S. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.045 · Cited by 657
Self-citation(2002) · PubMed · Cited by 640
Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms
Wang, S., Konorev, E. A., Kotamraju, S., Joseph, J., Kalivendi, S., & Kalyanaraman, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400944200 · Cited by 611
E1A signaling to p53 involves the p19ARFtumor suppressor
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 609
Self-citationReactive oxygen species are downstream mediators of p53-dependent apoptosis.
Johnson, T. M., Yu, Z. X., Ferrans, V. J., Lowenstein, R. A., & Finkel, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11848 · Cited by 596
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.
Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13777 · Cited by 583
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
“Recently, it has become clear that tumors with p53 mutations are relatively resistant to the classical DNA-damaging chemotherapeutics (Lowe et al. 1994; Smith and Fornace 1995; Giaccia and Kastan 1998; Schmitt et al. 1999), whereas agents such as taxol (Bacus et al. 2001) can cause p53independent…”
BackgroundThe role of p53 in determining sensitivity to radiotherapy
Gudkov, A. V., & Komarova, E. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc992 · Cited by 572
CELL CYCLE REGULATION AND APOPTOSIS
King, K. L., & Cidlowski, J. A. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.601 · Cited by 531
Overexpression of folate binding protein in ovarian cancers
Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., & Boiocchi, M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970422)74:2<193::aid-ijc10>3.0.co;2-f · Cited by 521
Death receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability
Yang, W. H., Kim, J. E., Nam, H. W., Ju, J. W., Kim, H. S., Kim, Y. S., & Cho, J. W. (2006) · Nature Cell Biology · doi:10.1038/ncb1470 · Cited by 486
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
Huang, C.-Y., Ju, D.-T., Chang, C.-F., Muralidhar Reddy, P., & Velmurugan, B. K. (2017) · BioMedicine · doi:10.1051/bmdcn/2017070423 · Cited by 481
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
The p53 network: cellular and systemic DNA damage responses in aging and Cancer
Reinhardt, H. C., & Schumacher, B. (2012) · Trends in Genetics · doi:10.1016/j.tig.2011.12.002 · Cited by 458
ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins
Waterman, M. J. F., Stavridi, E. S., Waterman, J. L. F., & Halazonetis, T. D. (1998) · Nature Genetics · doi:10.1038/542 · Cited by 460
Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 449
Venkatachalam, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4657 · Cited by 449
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
Chang, B.-D., Watanabe, K., Broude, E. V., Fang, J., Poole, J. C., Kalinichenko, T. V., & Roninson, I. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4291 · Cited by 432
Preferential induction of apoptosis for primary human leukemic stem cells
Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., & Jordan, C. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252462599 · Cited by 426
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415
Hwang, P. M., Bunz, F., Yu, J., Rago, C., Chan, T. A., Murphy, M. P., Kelso, G. F., Smith, R. A. J., Kinzler, K. W., & Vogelstein, B. (2001) · Nature Medicine · doi:10.1038/nm1001-1111 · Cited by 422
Kemeny, N. E., Niedzwiecki, D., Hollis, D. R., Lenz, H.-J., Warren, R. S., Naughton, M. J., Weeks, J. C., Sigurdson, E. R., Herndon, J. E., Zhang, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8166 · Cited by 417
PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family
Attardi, L. D., Reczek, E. E., Cosmas, C., Demicco, E. G., McCurrach, M. E., Lowe, S. W., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.14.6.704 · Cited by 397
Self-citationCollins, K., Jacks, T., & Pavletich, N. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.2776 · Cited by 380
Self-citationp53 and breast cancer, an update
Lacroix, M., Toillon, R.-A., & Leclercq, G. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380
McCurrach, M. E., Connor, T. M. F., Knudson, C. M., Korsmeyer, S. J., & Lowe, S. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2345 · Cited by 369
Self-citationElevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991 · Cited by 365
Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., & Huang, H.-J. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5724 · Cited by 363
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
APOPTOSIS AND DISEASE: Regulation and Clinical Relevance of Programmed Cell Death
M. Rudin, M., & B. Thompson, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.267 · Cited by 354
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Chinery, R., Brockman, J. A., Peeler, M. O., Shyr, Y., Beauchamp, R. D., & Coffey, R. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1233 · Cited by 334
Macleod, K. F., Hu, Y., & Jacks, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01006.x · Cited by 321
Self-citationAbrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene
Wang, X. W. (2003) · Hepatocellular Carcinoma · doi:10.1385/1-59259-079-9:57 · Cited by 321
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H., et al. (1996) · Genes & Development · doi:10.1101/gad.10.10.1219 · Cited by 313
Genetic alterations in breast cancer
Bièche, I., & Lidereau, R. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140402 · Cited by 303
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Dhandapani, K. M., Mahesh, V. B., & Brann, D. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04633.x · Cited by 298
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Expression of p53 and Prognosis in Children with Malignant Gliomas
Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., & Sposto, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012224 · Cited by 281
Significance of immunohistochemistry in breast cancer
Zaha, D. C. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.382 · Cited by 277
Circadian molecular clocks and cancer
Kelleher, F. C., Rao, A., & Maguire, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.09.040 · Cited by 276
Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., & Varmus, H. E. (1995) · Genes & Development · doi:10.1101/gad.9.7.882 · Cited by 276
Hypoxia, gene expression, and metastasis
Chan, D. A., & Giaccia, A. J. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9063-1 · Cited by 276
The promises and perils of p53
Krizhanovsky, V., & Lowe, S. W. (2009) · Nature · doi:10.1038/4601085a · Cited by 274
Self-citationKomarova, E. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1391 · Cited by 273
Czarnota, G. J., Kolios, M. C., Abraham, J., Portnoy, M., Ottensmeyer, F. P., Hunt, J. W., & Sherar, M. D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690724 · Cited by 273
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
STEIN, J. P., GROSSFELD, G. D., GINSBERG, D. A., ESRIG, D., FREEMAN, J. A., FIGUEROA, A. J., SKINNER, D. G., & COTE, R. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62747-2 · Cited by 271
p53 and treatment of bladder cancer
Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. (1997) · Nature · doi:10.1038/385123b0 · Cited by 269
pH-Responsive Capsules Engineered from Metal-Phenolic Networks for Anticancer Drug Delivery
Ping, Y., Guo, J., Ejima, H., Chen, X., Richardson, J. J., Sun, H., & Caruso, F. (2015) · Small · doi:10.1002/smll.201403343 · Cited by 269
A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy
Liu, J., Song, L., Liu, S., Jiang, Q., Liu, Q., Li, N., Wang, Z.-G., & Ding, B. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04812 · Cited by 267
Minn, A. J., Boise, L. H., & Thompson, C. B. (1996) · Genes & Development · doi:10.1101/gad.10.20.2621 · Cited by 263
Caspase-3 Promotes Genetic Instability and Carcinogenesis
Liu, X., He, Y., Li, F., Huang, Q., Kato, T. A., Hall, R. P., & Li, C.-Y. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.03.003 · Cited by 263
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
Molecular genetics, natural history and the demise of childhood leukaemia
Greaves, M. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00296-8 · Cited by 257
Smoking, p53 Mutation, and Lung Cancer
Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0539 · Cited by 255
Li, P.-X., Wong, J., Ayed, A., Ngo, D., Brade, A. M., Arrowsmith, C., Austin, R. C., & Klamut, H. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909580199 · Cited by 254
Cellular senescence and cancer treatment
Schmitt, C. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.005 · Cited by 254
mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234
(2001) · PubMed · Cited by 194
Transformation of normal human cells in the absence of telomerase activation
Seger, Y. R., Garcı́a-Cao, M., Piccinin, S., Cunsolo, C. L., Doglioni, C., Blasco, M. A., Hannon, G. J., & Maestro, R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00183-6 · Cited by 159
NFκB inhibitors induce cell death in glioblastomas
Zanotto-Filho, A., Braganhol, E., Schröder, R., de Souza, L. H. T., Dalmolin, R. J. S., Pasquali, M. A. B., Gelain, D. P., Battastini, A. M. O., & Moreira, J. C. F. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.014 · Cited by 117
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
Masuya, D., Huang, C., Liu, D., Nakashima, T., Yokomise, H., Ueno, M., Nakashima, N., & Sumitomo, S. (2006) · The Journal of Pathology · doi:10.1002/path.1931 · Cited by 103
Li, X., Peterson, Y. K., Inks, E. S., Himes, R. A., Li, J., Zhang, Y., Kong, X., & Chou, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00136 · Cited by 93
p53 is dispensable for UV-induced cell cycle arrest at late G1 in mammalian cells
Al-Mohanna, M. A., Al-Khodairy, F. M., Krezolek, Z., Bertilsson, P.-A., Al-Houssein, K. A., & Aboussekhra, A. (2001) · Carcinogenesis · doi:10.1093/carcin/22.4.573 · Cited by 30
Montuori, G., Tu, F., Qin, D., Schmargon, R., Rodriguez-Fos, E., Helmsauer, K., Hui, H., Mandal, S., Purshouse, K., Fankhänel, L., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1738 · Cited by 15
Metadata
- Authors
- Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T.
- Venue
- Science
- Published
- 1994-11-04
- Volume
- 266
- Issue
- 5186
- Pages
- 807-810
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2081894694
- Cited by
- 1,469
- References
- 21
- FWCI
- 38.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.